ADC – ANTIBODY-DRUG CONJUGATES IN ONCOLOGY
ADC are promising novel therapies for oncology patients.
Background: Antibody-drug conjugates (ADC) are a promising novel therapy for oncology patients as it combines tumor‑targeted antibodies with cytotoxic molecules resulting in improved therapeutic outcomes. Aim: The aim of this article is a thorough analysis of ADC possibilities in oncology focusing on treatment options, side effects of therapies for breast, bladder and lung cancers. Material and methods: A search of relevant research databases was conducted to identify eligible papers. Results: Findings reveal ADC to be a promising treatment option as a innovative, more precise form of therapy.
ADC represent a targeted, precision approach to cancer treatment, potentially improving outcomes and minimizing side‑effects compared to conventional chemotherapy.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC